Corrigendum: Alveolar macrophages in lung cancer: opportunities and challenges

Cheng-Yen Chang; Dominique Armstrong; David B Corry; Farrah Kheradmand

doi:10.3389/fimmu.2023.1328927

Corrigendum: Alveolar macrophages in lung cancer: opportunities and challenges

Front Immunol. 2023 Nov 6:14:1328927. doi: 10.3389/fimmu.2023.1328927. eCollection 2023.

Authors

Cheng-Yen Chang¹, Dominique Armstrong¹, David B Corry^{1

2

3

4}, Farrah Kheradmand^{1

2

3

4}

Affiliations

¹ Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
² Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
³ Biology of Inflammation Center, Baylor College of Medicine, Houston, TX, United States.
⁴ Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, TX, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1268939.].

Keywords: immune checkpoint inhibitors; lung cancer; smoking; tissue-resident alveolar macrophages; tumor microenvironment; tumor-associated macrophages.

Publication types

Published Erratum